12 Safe Stocks to Buy for the Long Term in 2025

7. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81 

Johnson & Johnson (NYSE:JNJ) researches and develops, manufactures, and sells various products in the healthcare field. There are various reasons why this company makes an excellent investment. First and foremost, as per the report for the fourth quarter of 2024, full-year reported sales growth reached 4.3% to $88.8 billion, with operational growth at 5.9% and adjusted operational growth at 5.4%. Moreover, operational growth excluding COVID-19 Vaccine was 7%, which demonstrates sustainable revenue growth from core operations, ensuring long-term financial stability and shareholder confidence. In addition to this, the company has acquired all outstanding shares of Intra-Cellular Therapies for $132 per share in cash for a total equity value of approximately $14.6 billion. This acquisition would differentiate the company’s portfolio and would serve as a strategic near- and long-term growth catalyst for the company, adding value to patients, health systems and shareholders. Lastly, the company has initiated the submission of an original New Drug Application with the US Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.